出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2024年2月
Recombinant Protein Market – Global Forecast To 2028
組換えタンパク質市場 : 製品（成長因子、ケモカイン、構造タンパク質、膜タンパク質）、用途（創薬＆開発（生物製剤、ワクチン、細胞＆遺伝子治療）、研究、バイオ医薬品生産）＆地域別 – 2028年までの世界予測
Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Research, Biopharma Production) & Region – Global Forecast to 2028
| ページ数 | 408 |
| 図表数 | 475 |
| 種別 | 英文調査報告書 |
| 価格 |
Report Overview
The global recombinant proteins market size is projected to reach USD 3.2 billion by 2028 from USD 2.2 billion in 2023, at a CAGR of 7.2% during the forecast period.
世界の組換えタンパク質市場規模は、予測期間中のCAGR 7.2%で、2023年の22億米ドルから2028年までに32億米ドルに達すると予測されています。
Factors such as rising demand for biologics & biosimilars due to patent expiry, increasing prevalence of chronic diseases, increased government support for life sciences research & development and growing preference for personalized medicine..
“The growth factors and chemokines segment segment held the dominant share in the recombinant proteins market”
Based on product, the global recombinant proteins market is segmented into growth factors and chemokines, kinase proteins, membrane proteins, immune response proteins, structural proteins, regulatory proteins, recombinant metabolic enzymes, adhesion molecules and receptors, and other recombinant proteins. The growth factors and chemokines segment is further segmented into interferons, interleukins and other growth factor & chemokines. The growth factors and chemokines segment is anticipated to grow at significant CAGR due to their application in cell culture, protein expression, and modulation of cellular responses.
“Drug discovery & development segment accounted for the largest share of the application segment in 2022.”
Based on application, the recombinant proteins market is segmented into, drug discovery and development, biopharmaceutical production, research, diagnostics, and other applications. In 2022, the drug discovery and development segment accounted for the largest share of the recombinant proteins market. The segment held the largest share in the market due to application of recombinant proteins in developing biopharmaceuticals and understanding the functions of potential drug targets.
“Asia Pacific region is likely to grow at a faster pace in the recombinant proteins market.”
The recombinant proteins market region is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by increasing demand for protein based drugs, rising government funding for recombinant proteins production and development of biotechnology-based drugs.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 70%, and Demand Side – 30%
• By Designation (Supply Side): Managers – 45%, CXOs & Directors – 30%, Executives- 25%
• By Region: North America: 40%, Europe: 25%, Asia Pacific: 20%, Latin America: 10%, and the Middle East and Africa: 5%
List of Companies Profiled in the Report:
• Bio-Techne (US)
• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• Abcam plc (UK)
• Abnova Corporation (Taiwan)
• Biolegend Inc (US)
• Bio-Rad Laboratories Inc. (US)
• BPS Bioscienc Inc (US)
• Enzo Biochem, Inc. (US)
• GenScript (China)
• Miltenyi Biotec B.V. & Co. KG (Germany)
• Proteintech Group, Inc. (US)
• Sino Biological Inc. (China)
• ACROBiosystems Group (US)
• Aviva Systems Biology Corporation (US)
• Sartorius CellGenix GmbH (Germany)
• Icosagen (Estonia)
• Neuromics (US)
• ProSpec-Tany Technogene Ltd. (Israel)
• ProteoGenix S.A.S (France)
• RayBiotech Inc (US)
• Lauraus Bio (India)
• Stemcell Technologies (Canada)
• StressMarq Biosciences Inc. (Canada)
• United States Biological (US)
Research Coverage:
This report provides a detailed picture of the recombinant proteins market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end-user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall recombinant proteins market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (rising incidence of chronic diseases, unleashing innovation in biologics and biosimilars with patent expiry, increasing government support for R&D in life sciences, growing preference for personalized medicine), restraints (high production costs, stringent regulatory approval processes), opportunities (advancements in gene editing technologies, high growth potential of emerging markets, emergence of novel expression systems) and challenges (challenges associated with delivery systems) are influencing the growth of recombinant proteins market.
• Product Development/Innovation: Detailed insights on newly launched products of the recombinant proteins market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the recombinant proteins market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the recombinant proteins market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Bio-Techne (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Abcam plc (UK), Abnova Corporation (Taiwan), Biolegend Inc (US), Bio-Rad Laboratories Inc. (US), BPS Bioscienc Inc (US), Enzo Biochem Inc. (US) and GenScript (China).
Table of Contents
1 INTRODUCTION 33
1.1 STUDY OBJECTIVES 33
1.2 MARKET DEFINITION 33
1.2.1 INCLUSIONS AND EXCLUSIONS 33
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
1.3.2 YEARS CONSIDERED 35
1.3.3 CURRENCY CONSIDERED 35
1.4 RESEARCH LIMITATIONS 35
1.5 STAKEHOLDERS 36
1.6 SUMMARY OF CHANGES 36
1.7 RECESSION IMPACT 37
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH DATA 38
FIGURE 1 RESEARCH DESIGN 38
2.1.1 SECONDARY DATA 39
2.1.2 PRIMARY DATA 40
FIGURE 2 RECOMBINANT PROTEINS MARKET: BREAKDOWN OF PRIMARIES 40
2.2 MARKET SIZE ESTIMATION 41
FIGURE 3 MARKET SIZE ESTIMATION: SUPPLY SIDE ANALYSIS (2022) 41
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 42
FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2022) 42
2.2.1 INSIGHTS FROM PRIMARIES 44
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 44
2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, APPLICATION, HOST CELL, AND END USER) 44
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 44
2.3 GROWTH RATE ASSUMPTIONS 45
FIGURE 8 RECOMBINANT PROTEINS MARKET: CAGR PROJECTIONS (2023–2028) 46
FIGURE 9 RECOMBINANT PROTEINS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 46
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 47
FIGURE 10 DATA TRIANGULATION METHODOLOGY 47
2.5 STUDY ASSUMPTIONS 48
2.6 RISK ANALYSIS 48
2.7 RECESSION IMPACT ANALYSIS 48
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024−2028 (% GROWTH) 49
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 49
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 49
3 EXECUTIVE SUMMARY 50
FIGURE 11 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 50
FIGURE 12 RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 51
FIGURE 13 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2023 VS. 2028 (USD MILLION) 51
FIGURE 14 RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2023 VS. 2028 (USD MILLION) 52
FIGURE 15 RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2023 VS. 2028 (USD MILLION) 53
FIGURE 16 RECOMBINANT PROTEINS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 54
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF RECOMBINANT PROTEINS MARKET 55
4 PREMIUM INSIGHTS 56
4.1 RECOMBINANT PROTEINS MARKET OVERVIEW 56
FIGURE 18 INCREASING GOVERNMENT SUPPORT FOR R&D IN LIFE SCIENCES TO DRIVE MARKET 56
4.2 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT (2022) 57
FIGURE 19 GROWTH FACTORS & CHEMOKINES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 57
4.3 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2023 VS. 2028 58
FIGURE 20 GROWTH FACTORS & CHEMOKINES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 58
4.4 RECOMBINANT PROTEINS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 58
FIGURE 21 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 58
5 MARKET OVERVIEW 59
5.1 INTRODUCTION 59
5.2 MARKET DYNAMICS 59
FIGURE 22 RECOMBINANT PROTEINS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 59
TABLE 4 RECOMBINANT PROTEINS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
5.2.1 DRIVERS 60
5.2.1.1 Rising incidence of chronic diseases 60
FIGURE 23 NUMBER OF CANCER CASES IN US (2017 – 2022) 61
5.2.1.2 Increasing demand for biologics and biosimilars due to patent expiry 62
5.2.1.3 Increasing government support for R&D in life sciences 63
TABLE 5 GOVERNMENT FUNDING FOR LIFE SCIENCE RESEARCH (2022) 63
5.2.1.4 Growing preference for personalized medicine 64
5.2.2 RESTRAINTS 64
5.2.2.1 High production costs 64
5.2.2.2 Stringent regulatory approval processes 65
5.2.3 OPPORTUNITIES 66
5.2.3.1 Advancements in gene editing technologies 66
5.2.3.2 High growth potential of emerging markets 67
5.2.3.3 Emergence of novel expression systems 68
5.2.4 CHALLENGES 69
5.2.4.1 Challenges associated with delivery systems 69
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 69
FIGURE 24 REVENUE SHIFTS AND NEW REVENUE POCKETS FOR RECOMBINANT PROTEIN MANUFACTURERS 69
5.4 PRICING ANALYSIS 70
5.4.1 AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYERS 70
TABLE 6 RECOMBINANT PROTEIN PRODUCTS 70
5.4.2 AVERAGE SELLING PRICE TREND OF RECOMBINANT PROTEINS 74
5.5 TECHNOLOGY ANALYSIS 74
5.6 VALUE CHAIN ANALYSIS 75
FIGURE 25 VALUE CHAIN ANALYSIS: MANUFACTURING & ASSEMBLY PHASE CONTRIBUTES MAXIMUM VALUE TO VALUE CHAIN OF RECOMBINANT PROTEINS 76
5.7 ECOSYSTEM MARKET/MAP 77
FIGURE 26 ECOSYSTEM MARKET/MAP 77
TABLE 7 RECOMBINANT PROTEINS MARKET: ROLE IN ECOSYSTEM: 77
5.8 REGULATORY ANALYSIS 79
TABLE 8 KEY REGULATORY AGENCIES 79
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83
TABLE 12 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83
TABLE 13 MIDDLE EAST: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84
TABLE 14 AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84
5.9 PORTER’S FIVE FORCES ANALYSIS 85
TABLE 15 RECOMBINANT PROTEINS MARKET: PORTER’S FIVE FORCES ANALYSIS 85
5.9.1 THREAT OF NEW ENTRANTS 85
5.9.2 THREAT OF SUBSTITUTES 85
5.9.3 BARGAINING POWER OF SUPPLIERS 86
5.9.4 BARGAINING POWER OF BUYERS 86
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 86
5.10 PATENT ANALYSIS 87
FIGURE 27 PATENT APPLICATIONS FOR RECOMBINANT PROTEINS, DECEMBER 2013–DECEMBER 2023 87
TABLE 16 RECOMBINANT PROTEINS MARKET: INDICATIVE LIST OF PATENTS 87
5.11 KEY CONFERENCES AND EVENTS 89
TABLE 17 DETAILED LIST OF KEY CONFERENCES AND EVENTS (2023–2024) 89
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 90
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 90
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RECOMBINANT PROTEINS 90
5.12.2 BUYING CRITERIA FOR RECOMBINANT PROTEINS 91
FIGURE 29 KEY BUYING CRITERIA FOR END USERS 91
6 RECOMBINANT PROTEINS MARKET, BY PRODUCT 92
6.1 INTRODUCTION 93
TABLE 18 RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 93
6.2 GROWTH FACTORS & CHEMOKINES 93
TABLE 19 RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY REGION, 2021–2028 (USD MILLION) 95
TABLE 20 RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 95
TABLE 21 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 22 EUROPE: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 23 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 24 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 25 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, COUNTRY, 2021–2028 (USD MILLION) 98
6.2.1 INTERFERONS (IFNS) 98
6.2.1.1 Ability to regulate critical cellular processes across research applications to propel market 98
TABLE 26 RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY REGION, 2021–2028 (USD MILLION) 99
TABLE 27 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 28 EUROPE: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 29 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 30 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 31 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INTERFERONS, BY COUNTRY, 2021–2028 (USD MILLION) 102
6.2.2 INTERLEUKINS (ILS) 102
6.2.2.1 Rising focus on personalized therapeutics to drive market 102
TABLE 32 RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY REGION, 2021–2028 (USD MILLION) 103
TABLE 33 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 34 EUROPE: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 35 ASAI PACIFIC: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 36 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 37 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INTERLEUKINS, BY COUNTRY, 2021–2028 (USD MILLION) 105
6.2.3 OTHER GROWTH FACTORS & CHEMOKINES 105
TABLE 38 RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY REGION, 2021–2028 (USD MILLION) 106
TABLE 39 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 40 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 41 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 42 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 43 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER GROWTH FACTORS & CHEMOKINES, BY COUNTRY, 2021–2028 (USD MILLION) 108
6.3 IMMUNE RESPONSE PROTEINS 109
6.3.1 HIGH UTILIZATION OF IMMUNE CHECKPOINT PROTEINS IN CANCER IMMUNOTHERAPY TO PROPEL MARKET 109
TABLE 44 RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY REGION, 2021–2028 (USD MILLION) 109
TABLE 45 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 46 EUROPE: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 47 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 48 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 49 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR IMMUNE RESPONSE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 112
6.4 STRUCTURAL PROTEINS 112
6.4.1 ATTACHMENT FACTORS IN CELL CULTURE APPLICATIONS TO DRIVE MARKET 112
TABLE 50 RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY REGION, 2021–2028 (USD MILLION) 113
TABLE 51 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 52 EUROPE: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 53 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 54 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 55 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR STRUCTURAL PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 116
6.5 MEMBRANE PROTEINS 116
6.5.1 ESSENTIAL PROCESS REGULATION OF STRUCTURAL CELLS TO SUPPORT MARKET GROWTH 116
TABLE 56 RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY REGION, 2021–2028 (USD MILLION) 117
TABLE 57 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 58 EUROPE: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 59 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 60 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 61 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR MEMBRANE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 119
6.6 KINASE PROTEINS 119
6.6.1 ACTIVE METABOLIZATION OF LIPIDS AND NUCLEOTIDES TO DRIVE MARKET 119
TABLE 62 RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY REGION, 2021–2028 (USD MILLION) 120
TABLE 63 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 64 EUROPE: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 65 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 66 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 67 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR KINASE PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 122
6.7 REGULATORY PROTEINS 122
6.7.1 ABILITY TO MODULATE CELLULAR PROCESSES TO DRIVE MARKET 122
TABLE 68 RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY REGION, 2021–2028 (USD MILLION) 123
TABLE 69 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 70 RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS IN EUROPE, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 71 EUROPE: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 72 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 73 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR REGULATORY PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 125
6.8 RECOMBINANT METABOLIC ENZYMES 126
6.8.1 HIGH ADOPTION IN BIOTECHNOLOGICAL APPLICATIONS FOR THERAPEUTIC DEVELOPMENT TO BOOST DEMAND 126
TABLE 74 RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY REGION, 2021–2028 (USD MILLION) 126
TABLE 75 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 76 EUROPE: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 77 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 78 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 79 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RECOMBINANT METABOLIC ENZYMES, BY COUNTRY, 2021–2028 (USD MILLION) 129
6.9 ADHESION MOLECULES & RECEPTORS 129
6.9.1 ENHANCED FACILITATION OF EXTRACELLULAR MATRIX INTERACTIONS TO SUPPORT MARKET GROWTH 129
TABLE 80 RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY REGION, 2021–2028 (USD MILLION) 130
TABLE 81 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 82 EUROPE: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 83 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 84 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 85 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ADHESION MOLECULES & RECEPTORS, BY COUNTRY, 2021–2028 (USD MILLION) 132
6.10 OTHER RECOMBINANT PROTEINS 132
TABLE 86 RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY REGION, 2021–2028 (USD MILLION) 133
TABLE 87 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 88 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 89 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 90 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 91 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER RECOMBINANT PROTEINS, BY COUNTRY, 2021–2028 (USD MILLION) 135
7 RECOMBINANT PROTEINS MARKET, BY APPLICATION 136
7.1 INTRODUCTION 137
TABLE 92 RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 137
7.2 DRUG DISCOVERY & DEVELOPMENT 137
TABLE 93 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 94 RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION) 138
TABLE 95 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 96 EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 97 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 98 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 99 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 141
7.2.1 BIOLOGICS 141
7.2.1.1 High adoption in autoimmune disease & cancer treatment to propel market 141
TABLE 100 RECOMBINANT PROTEINS MARKET: KEY BIOLOGICS AND INDICATIONS 141
TABLE 101 RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY REGION, 2021–2028 (USD MILLION) 142
TABLE 102 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 103 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 104 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 105 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 106 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOLOGICS, BY COUNTRY, 2021–2028 (USD MILLION) 144
7.2.2 VACCINES 144
7.2.2.1 Rising incidence of infectious diseases to boost demand 144
TABLE 107 RECOMBINANT PROTEINS MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION) 145
TABLE 108 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 109 EUROPE: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 110 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 111 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 112 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION) 147
7.2.3 CELL & GENE THERAPY 147
7.2.3.1 Growing focus on CAR-T therapies to propel market 147
TABLE 113 RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION) 148
TABLE 114 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 149
TABLE 115 EUROPE: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 149
TABLE 116 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 117 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 118 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 151
7.3 RESEARCH 151
TABLE 119 RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 120 RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY REGION, 2021–2028 USD MILLION) 152
TABLE 121 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 152
TABLE 122 EUROPE: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 123 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 124 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 154
TABLE 125 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 154
7.3.1 ACADEMIC RESEARCH 154
7.3.1.1 Wide application in molecular & gene expression studies to propel market 154
TABLE 126 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY REGION, 2021–2028 (USD MILLION) 155
TABLE 127 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 155
TABLE 128 EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH STUDIES, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 129 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 130 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 157
TABLE 131 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 157
7.3.2 BIOTECHNOLOGY RESEARCH 157
7.3.2.1 Growing focus on bioengineering and genomics to fuel market 157
TABLE 132 RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY REGION, 2021–2028 (USD MILLION) 158
TABLE 133 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 159
TABLE 134 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 159
TABLE 135 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 160
TABLE 136 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 160
TABLE 137 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 161
7.4 BIOPHARMACEUTICAL PRODUCTION 161
7.4.1 INCREASING DEVELOPMENT OF PROTEIN-BASED DRUGS TO SUPPORT MARKET GROWTH 161
TABLE 138 RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2021–2028 (USD MILLION) 162
TABLE 139 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 162
TABLE 140 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 141 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 142 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 143 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION) 164
7.5 DIAGNOSTICS 164
7.5.1 GROWING FOCUS ON EARLY DISEASE DETECTION TO DRIVE MARKET 164
TABLE 144 RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 165
TABLE 145 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 146 EUROPE: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 166
TABLE 147 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 166
TABLE 148 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 149 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 167
7.6 OTHER APPLICATIONS 167
TABLE 150 RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 168
TABLE 151 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 152 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 169
TABLE 153 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 169
TABLE 154 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 155 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 170
8 RECOMBINANT PROTEINS MARKET, BY HOST CELL 171
8.1 INTRODUCTION 172
TABLE 156 RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 172
8.2 MAMMALIAN SYSTEMS 172
8.2.1 HIGH UPTAKE IN BIOTECHNOLOGY APPLICATIONS TO PROPEL MARKET 172
TABLE 157 RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY REGION, 2021–2028 (USD MILLION) 173
TABLE 158 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 173
TABLE 159 EUROPE: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 174
TABLE 160 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 174
TABLE 161 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 162 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR MAMMALIAN SYSTEMS, BY COUNTRY, 2021–2028 (USD MILLION) 175
8.3 INSECT CELLS 175
8.3.1 COST-EFFICIENT AND HIGH-YIELD CHARACTERISTICS TO DRIVE MARKET 175
TABLE 163 RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY REGION, 2021–2028 (USD MILLION) 176
TABLE 164 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 177
TABLE 165 EUROPE: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 177
TABLE 166 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 178
TABLE 167 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 178
TABLE 168 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR INSECT CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 179
8.4 YEAST & FUNGI 179
8.4.1 NEW APPLICATIONS IN VACCINE DEVELOPMENT AND DIABETES TREATMENT TO BOOST DEMAND 179
TABLE 169 RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY REGION, 2021–2028 (USD MILLION) 180
TABLE 170 RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION) 180
TABLE 171 RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION) 181
TABLE 172 RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION) 181
TABLE 173 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION) 182
TABLE 174 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR YEAST & FUNGI, BY COUNTRY, 2021–2028 (USD MILLION) 182
8.5 BACTERIAL CELLS 182
8.5.1 SIMPLIFIED GENETIC MANIPULATION AND SCALABILITY ADVANTAGES TO DRIVE MARKET 182
TABLE 175 RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY REGION, 2021–2028 (USD MILLION) 183
TABLE 176 RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 184
TABLE 177 RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 184
TABLE 178 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 185
TABLE 179 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 185
TABLE 180 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 185
8.6 OTHER HOST CELLS 186
TABLE 181 RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY REGION, 2021–2028 (USD MILLION) 186
TABLE 182 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 187
TABLE 183 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 187
TABLE 184 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 188
TABLE 185 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 188
TABLE 186 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER HOST CELLS, BY COUNTRY, 2021–2028 (USD MILLION) 189
9 RECOMBINANT PROTEINS MARKET, BY END USER 190
9.1 INTRODUCTION 191
TABLE 187 RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 191
9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 191
9.2.1 RISING DEVELOPMENT OF GENE THERAPIES AND VACCINES TO PROPEL MARKET 191
TABLE 188 RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION) 193
TABLE 189 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 193
TABLE 190 EUROPE: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 194
TABLE 191 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 194
TABLE 192 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 195
TABLE 193 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 195
9.3 BIOTECHNOLOGY COMPANIES 195
9.3.1 RISING NUMBER OF PROTEIN-BASED RESEARCH PROJECTS TO BOOST DEMAND 195
TABLE 194 RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 196
TABLE 195 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 196
TABLE 196 EUROPE: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 197
TABLE 197 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 197
TABLE 198 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 198
TABLE 199 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 198
9.4 ACADEMIC & RESEARCH INSTITUTES 199
9.4.1 FAVORABLE GOVERNMENT INVESTMENTS TO PROPEL MARKET 199
TABLE 200 RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 200
TABLE 201 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 200
TABLE 202 EUROPE: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 201
TABLE 203 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 201
TABLE 204 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 202
TABLE 205 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 202
9.5 CONTRACT RESEARCH ORGANIZATIONS 202
9.5.1 RISING OUTSOURCING OF CLINICAL TRIAL SERVICES TO SUPPORT MARKET GROWTH 202
TABLE 206 RECOMBINANT PROTEINS MARKET FOR CROS, BY REGION, 2021–2028 (USD MILLION) 203
TABLE 207 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION) 203
TABLE 208 EUROPE: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION) 204
TABLE 209 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION) 204
TABLE 210 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION) 205
TABLE 211 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR CROS, BY COUNTRY, 2021–2028 (USD MILLION) 205
9.6 OTHER END USERS 205
TABLE 212 RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 206
TABLE 213 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 206
TABLE 214 EUROPE: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 207
TABLE 215 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 207
TABLE 216 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 USD MILLION) 208
TABLE 217 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 208
10 RECOMBINANT PROTEINS MARKET, BY REGION 209
10.1 INTRODUCTION 210
TABLE 218 RECOMBINANT PROTEINS MARKET, BY REGION, 2021–2028 (USD MILLION) 210
10.2 NORTH AMERICA 210
FIGURE 30 NORTH AMERICA: RECOMBINANT PROTEINS MARKET SNAPSHOT 211
TABLE 219 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 212
TABLE 220 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 212
TABLE 221 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 213
TABLE 222 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 213
TABLE 223 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 214
TABLE 224 NORTH AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 214
TABLE 225 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 USD MILLION) 215
TABLE 226 NORTH AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 215
10.2.1 NORTH AMERICA: RECESSION IMPACT 215
10.2.2 US 216
10.2.2.1 Rising investments in life sciences research to drive market 216
TABLE 227 US: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 217
TABLE 228 US: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 217
TABLE 229 US: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 218
TABLE 230 US: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 218
TABLE 231 US: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 218
TABLE 232 US: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 219
TABLE 233 US: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 219
10.2.3 CANADA 219
10.2.3.1 High incidence of cancer and favorable healthcare investments to drive market 219
TABLE 234 CANADA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 220
TABLE 235 CANADA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 221
TABLE 236 CANADA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 221
TABLE 237 CANADA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 222
TABLE 238 CANADA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 222
TABLE 239 CANADA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 222
TABLE 240 CANADA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 223
10.3 EUROPE 223
TABLE 241 EUROPE: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 224
TABLE 242 EUROPE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 224
TABLE 243 EUROPE: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 225
TABLE 244 EUROPE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 225
TABLE 245 EUROPE: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 226
TABLE 246 EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 226
TABLE 247 EUROPE: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 227
TABLE 248 EUROPE: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 227
10.3.1 EUROPE: RECESSION IMPACT 228
10.3.2 GERMANY 228
10.3.2.1 Growing focus on biotech clusters to drive market 228
TABLE 249 GERMANY: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 229
TABLE 250 GERMANY: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 229
TABLE 251 GERMANY: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 230
TABLE 252 GERMANY: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 230
TABLE 253 GERMANY: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 231
TABLE 254 GERMANY: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 231
TABLE 255 GERMANY: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 232
10.3.3 UK 232
10.3.3.1 Rising demand for biologics and biosimilars to propel market 232
TABLE 256 UK: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 233
TABLE 257 UK: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 233
TABLE 258 UK: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 234
TABLE 259 UK: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 234
TABLE 260 UK: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 235
TABLE 261 UK: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 235
TABLE 262 UK: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 236
10.3.4 FRANCE 236
10.3.4.1 Rising establishment of biopharmaceutical production facilities to boost demand 236
TABLE 263 FRANCE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 237
TABLE 264 FRANCE: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 238
TABLE 265 FRANCE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 238
TABLE 266 FRANCE: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 239
TABLE 267 FRANCE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 239
TABLE 268 FRANCE: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 239
TABLE 269 FRANCE: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 240
10.3.5 ITALY 240
10.3.5.1 Growth in proteomics and genomics research to drive market 240
TABLE 270 ITALY: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 241
TABLE 271 ITALY: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 241
TABLE 272 ITALY: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 242
TABLE 273 ITALY: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 242
TABLE 274 ITALY: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 243
TABLE 275 ITALY: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 243
TABLE 276 ITALY: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 244
10.3.6 SPAIN 244
10.3.6.1 Rising establishment of pharmaceutical production facilities to drive market 244
TABLE 277 SPAIN: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 245
TABLE 278 SPAIN: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 245
TABLE 279 SPAIN: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 246
TABLE 280 SPAIN: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 246
TABLE 281 SPAIN: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 247
TABLE 282 SPAIN: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 247
TABLE 283 SPAIN: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 248
10.3.7 REST OF EUROPE 248
TABLE 284 REST OF EUROPE: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 249
TABLE 285 REST OF EUROPE: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 249
TABLE 286 REST OF EUROPE: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 250
TABLE 287 REST OF EUROPE: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 250
TABLE 288 REST OF EUROPE: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 251
TABLE 289 REST OF EUROPE: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 251
TABLE 290 REST OF EUROPE: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 252
10.4 ASIA PACIFIC 252
FIGURE 31 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET SNAPSHOT 253
TABLE 291 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY REGION, 2021–2028 (USD MILLION) 254
TABLE 292 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 254
TABLE 293 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 255
TABLE 294 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 255
TABLE 295 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RESEARCH APPLICATION, BY TYPE, 2021–2028 (USD MILLION) 256
TABLE 296 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATION, BY TYPE, 2021–2028 (USD MILLION) 256
TABLE 297 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 257
TABLE 298 ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 257
10.4.1 ASIA PACIFIC: RECESSION IMPACT 258
10.4.2 CHINA 258
10.4.2.1 Expansion of R&D infrastructure to support market growth 258
TABLE 299 CHINA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 259
TABLE 300 CHINA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 259
TABLE 301 CHINA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 260
TABLE 302 CHINA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 260
TABLE 303 CHINA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 261
TABLE 304 CHINA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 261
TABLE 305 CHINA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 262
10.4.3 JAPAN 262
10.4.3.1 Growth in pharmaceutical industry to propel market 262
TABLE 306 JAPAN: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 263
TABLE 307 JAPAN: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 263
TABLE 308 JAPAN: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 264
TABLE 309 JAPAN: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 264
TABLE 310 JAPAN: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 265
TABLE 311 JAPAN: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 265
TABLE 312 JAPAN: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 266
10.4.4 INDIA 266
10.4.4.1 Rising demand for drug discovery & development to propel market 266
TABLE 313 INDIA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 267
TABLE 314 INDIA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 268
TABLE 315 INDIA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 268
TABLE 316 INDIA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 269
TABLE 317 INDIA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 269
TABLE 318 INDIA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 270
TABLE 319 INDIA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 270
10.4.5 SOUTH KOREA 271
10.4.5.1 Rising incidence of infectious diseases to drive market 271
TABLE 320 SOUTH KOREA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 272
TABLE 321 SOUTH KOREA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 272
TABLE 322 SOUTH KOREA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 273
TABLE 323 SOUTH KOREA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 273
TABLE 324 SOUTH KOREA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 274
TABLE 325 SOUTH KOREA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 274
TABLE 326 SOUTH KOREA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 275
10.4.6 REST OF ASIA PACIFIC 275
TABLE 327 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 276
TABLE 328 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 276
TABLE 329 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 277
TABLE 330 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 277
TABLE 331 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 278
TABLE 332 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 278
TABLE 333 REST OF ASIA PACIFIC: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 279
10.5 LATIN AMERICA 279
TABLE 334 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 279
TABLE 335 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 280
TABLE 336 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 280
TABLE 337 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 281
TABLE 338 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 281
TABLE 339 LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 282
TABLE 340 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 282
TABLE 341 LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 283
10.5.1 LATIN AMERICA: RECESSION IMPACT 283
10.5.2 BRAZIL 284
10.5.2.1 Rising incidence of chronic diseases to drive market 284
TABLE 342 BRAZIL: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 284
TABLE 343 BRAZIL: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 285
TABLE 344 BRAZIL: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 285
TABLE 345 BRAZIL: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 286
TABLE 346 BRAZIL: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 286
TABLE 347 BRAZIL: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 287
TABLE 348 BRAZIL: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 287
10.5.3 REST OF LATIN AMERICA 288
TABLE 349 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 288
TABLE 350 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 289
TABLE 351 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 289
TABLE 352 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 290
TABLE 353 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 290
TABLE 354 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 291
TABLE 355 REST OF LATIN AMERICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 291
10.6 MIDDLE EAST 292
TABLE 356 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY REGION, 2021–2028 (USD MILLION) 292
TABLE 357 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 293
TABLE 358 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 293
TABLE 359 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 294
TABLE 360 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 294
TABLE 361 MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 295
TABLE 362 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 295
TABLE 363 MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 296
10.6.1 MIDDLE EAST: RECESSION IMPACT 296
10.6.2 GCC COUNTRIES 296
10.6.2.1 Rising government investments in healthcare to support market growth 296
TABLE 364 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 297
TABLE 365 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 298
TABLE 366 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 298
TABLE 367 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 299
TABLE 368 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 299
TABLE 369 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 300
TABLE 370 GCC COUNTRIES: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 300
10.6.3 REST OF THE MIDDLE EAST 301
TABLE 371 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 301
TABLE 372 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 302
TABLE 373 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 302
TABLE 374 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 303
TABLE 375 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 303
TABLE 376 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 304
TABLE 377 REST OF THE MIDDLE EAST: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 304
10.7 AFRICA 305
10.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH 305
TABLE 378 AFRICA: RECOMBINANT PROTEINS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 306
TABLE 379 AFRICA: RECOMBINANT PROTEINS MARKET FOR GROWTH FACTORS & CHEMOKINES, BY TYPE, 2021–2028 (USD MILLION) 306
TABLE 380 AFRICA: RECOMBINANT PROTEINS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 307
TABLE 381 AFRICA: RECOMBINANT PROTEINS MARKET FOR RESEARCH, BY TYPE, 2021–2028 (USD MILLION) 307
TABLE 382 AFRICA: RECOMBINANT PROTEINS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2021–2028 (USD MILLION) 308
TABLE 383 AFRICA: RECOMBINANT PROTEINS MARKET, BY HOST CELL, 2021–2028 (USD MILLION) 308
TABLE 384 AFRICA: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028 (USD MILLION) 309
10.7.2 AFRICA: RECESSION IMPACT 309
11 COMPETITIVE LANDSCAPE 310
11.1 INTRODUCTION 310
11.2 KEY PLAYER STRATEGIES 311
FIGURE 32 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 311
11.3 REVENUE SHARE ANALYSIS 312
FIGURE 33 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2020−2022) 312
11.4 MARKET SHARE ANALYSIS 312
FIGURE 34 RECOMBINANT PROTEINS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022) 313
TABLE 385 RECOMBINANT PROTEINS MARKET: INTENSITY OF COMPETITIVE RIVALRY 313
11.5 COMPANY EVALUATION MATRIX 314
FIGURE 35 RECOMBINANT PROTEINS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 315
11.5.1 STARS 315
11.5.2 EMERGING LEADERS 315
11.5.3 PERVASIVE PLAYERS 316
11.5.4 PARTICIPANTS 316
11.5.5 COMPETITIVE BENCHMARKING 316
11.5.5.1 Product footprint (15 companies) 316
TABLE 386 RECOMBINANT PROTEINS MARKET: COMPANY PRODUCT FOOTPRINT 316
11.5.5.2 Regional footprint 317
TABLE 387 RECOMBINANT PROTEINS MARKET: REGIONAL FOOTPRINT ANALYSIS 317
11.6 START-UP/SME EVALUATION MATRIX 318
11.6.1 PROGRESSIVE COMPANIES 318
11.6.2 STARTING BLOCKS 318
11.6.3 RESPONSIVE COMPANIES 318
11.6.4 DYNAMIC COMPANIES 318
FIGURE 36 RECOMBINANT PROTEINS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022) 319
11.6.5 COMPETITIVE BENCHMARKING OF START-UPS/SMES 320
TABLE 388 RECOMBINANT PROTEINS MARKET: PRODUCT FOOTPRINT 320
TABLE 389 RECOMBINANT PROTEINS MARKET: REGIONAL FOOTPRINT 320
11.7 COMPETITIVE SCENARIO 321
11.7.1 PRODUCT LAUNCHES & APPROVALS 321
TABLE 390 RECOMBINANT PROTEINS MARKET: PRODUCT LAUNCHES & APPROVALS, (JANUARY 2021–SEPTEMBER 2023) 321
11.7.2 DEALS 322
TABLE 391 RECOMBINANT PROTEINS MARKET: DEALS (JANUARY 2021−SEPTEMBER 2023) 322
11.7.3 OTHER DEVELOPMENTS 323
TABLE 392 RECOMBINANT PROTEINS MARKET: OTHER DEVELOPMENTS (JANUARY 2021−SEPTEMBER 2023) 323
12 COMPANY PROFILES 324
(Business overview, Products offered, Recent developments & MnM View)*
12.1 KEY PLAYERS 324
12.1.1 BIO-TECHNE 324
TABLE 393 BIO-TECHNE: BUSINESS OVERVIEW 324
FIGURE 37 BIO‑TECHNE: COMPANY SNAPSHOT (2022) 325
TABLE 394 BIO‑TECHNE: PRODUCTS OFFERED 325
TABLE 395 BIO-TECHNE: DEALS 329
TABLE 396 BIO-TECHNE: OTHER DEVELOPMENTS 330
12.1.2 THERMO FISHER SCIENTIFIC INC. 331
TABLE 397 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 331
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 332
TABLE 398 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 332
TABLE 399 THERMO FISHER SCIENTIFIC INC: DEALS 337
12.1.3 MERCK KGAA 338
TABLE 400 MERCK KGAA: BUSINESS OVERVIEW 338
FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT (2022) 339
TABLE 401 MERCK KGAA: PRODUCTS OFFERED 339
TABLE 402 MERCK KGAA: DEALS 340
TABLE 403 MERCK KGAA: OTHER DEVELOPMENTS 340
12.1.4 ABCAM PLC 342
TABLE 404 ABCAM PLC: BUSINESS OVERVIEW 342
FIGURE 40 ABCAM PLC: COMPANY SNAPSHOT (2022) 343
TABLE 405 ABCAM PLC: PRODUCTS OFFERED 343
TABLE 406 ABCAM PLC: DEALS 346
TABLE 407 ABCAM PLC: OTHER DEVELOPMENTS 346
12.1.5 ABNOVA CORPORATION 348
TABLE 408 ABNOVA CORPORATION: BUSINESS OVERVIEW 348
TABLE 409 ABNOVA CORPORATION: PRODUCTS OFFERED 348
12.1.6 BIOLEGEND, INC 350
TABLE 410 BIOLEGEND INC: BUSINESS OVERVIEW 350
TABLE 411 BIOLEGEND INC: PRODUCTS OFFERED 351
12.1.7 BIO-RAD LABORATORIES, INC. 353
TABLE 412 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 353
FIGURE 41 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 354
TABLE 413 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 354
12.1.8 BPS BIOSCIENCE, INC. 358
TABLE 414 BPS BIOSCIENCE, INC.: BUSINESS OVERVIEW 358
TABLE 415 BPS BIOSCIENCE, INC.: PRODUCTS OFFERED 359
12.1.9 ENZO LIFE SCIENCES, INC. (SUBSIDIARY OF ENZO BIOCHEM, INC.) 360
TABLE 416 ENZO BIOCHEM, INC.: BUSINESS OVERVIEW 360
FIGURE 42 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2022) 361
TABLE 417 ENZO BIOCHEM, INC.: PRODUCTS OFFERED 361
TABLE 418 ENZO BIOCHEM, INC.: OTHER DEVELOPMENTS 366
12.1.10 GENSCRIPT 367
TABLE 419 GENSCRIPT: BUSINESS OVERVIEW 367
FIGURE 43 GENSCRIPT: COMPANY SNAPSHOT (2022) 368
TABLE 420 GENSCRIPT: PRODUCTS OFFERED 369
12.1.11 MILTENYI BIOTEC B.V. & CO. KG 372
TABLE 421 MILTENYI BIOTEC B.V. & CO. KG: BUSINESS OVERVIEW 372
TABLE 422 MILTENYI BIOTEC B.V. & CO. KG: PRODUCTS OFFERED 372
TABLE 423 MILTENYI BIOTEC B.V. & CO. KG: PRODUCT LAUNCHES 373
12.1.12 PROTEINTECH GROUP, INC. 374
TABLE 424 PROTEINTECH GROUP, INC.: BUSINESS OVERVIEW 374
TABLE 425 PROTEINTECH GROUP, INC.: PRODUCTS OFFERED 374
TABLE 426 PROTEINTECH GROUP, INC.: DEALS 377
TABLE 427 PROTEINTECH GROUP, INC.: OTHER DEVELOPMENTS 378
12.1.13 SINO BIOLOGICAL, INC. 379
TABLE 428 SINO BIOLOGICAL, INC.: BUSINESS OVERVIEW 379
TABLE 429 SINO BIOLOGICAL, INC.: PRODUCTS OFFERED 379
TABLE 430 SINO BIOLOGICAL, INC.: PRODUCT LAUNCHES 381
TABLE 431 SINO BIOLOGICAL, INC.: DEALS 381
TABLE 432 SINO BIOLOGICAL, INC.: OTHER DEVELOPMENTS 381
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS 382
12.2.1 ACROBIOSYSTEMS GROUP 382
12.2.2 AVIVA SYSTEMS BIOLOGY CORPORATION 384
12.2.3 SARTORIUS CELLGENIX GMBH 385
12.2.4 ICOSAGEN 386
12.2.5 NEUROMICS 387
12.2.6 PROSPEC-TANY TECHNOGENE LTD. 388
12.2.7 PROTEOGENIX S.A.S 393
12.2.8 RAYBIOTECH, INC. 394
12.2.9 LAURUS BIO 395
12.2.10 STEMCELL TECHNOLOGIES 396
12.2.11 STRESSMARQ BIOSCIENCES INC. 397
12.2.12 UNITED STATES BIOLOGICAL 398
13 APPENDIX 399
13.1 DISCUSSION GUIDE 399
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 403
13.3 CUSTOMIZATION OPTIONS 405
13.4 RELATED REPORTS 405
13.5 AUTHOR DETAILS 406